Evidence map›Paper›PMID 11011112›Full record

ArticleJapanese journal of cancer research : Gann2000

A novel gene "Niban" upregulated in renal carcinogenesis: cloning by the cDNA-amplified fragment length polymorphism approach.

S Majima, K Kajino, T Fukuda, F Otsuka, O Hino

Open access · bronzeAbstract read
In one paragraph

Article in Japanese journal of cancer research : Gann, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Frontiers in cell and developmental biology · 2022
    Review
  3. Article
  4. A cell permeant phosphopeptide mimetic of Niban inhibits p38 MAPK and restores endothelial function after injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S MajimaDepartment of Experimental Pathology, Cancer Institute, Toshima-ku, Tokyo 170-8455, Japan.
K Kajino
T Fukuda
F Otsuka
O Hino
The Cancer Institute Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A modified AFLP (amplified fragment length polymorphism) method was employed to isolate genes differentially expressed in renal carcinogenesis of Tsc2 gene mutant (Eker) rats. One gene, selected for further investigation, was named "Niban" "second" in Japanese), because it is the second new gene to be found after Erc (expressed in renal carcinoma) in our laboratory. Importantly, "Niban" is well expressed even in small primary rat Eker renal tumors, more than in progressed cell lines, and is also expressed in human renal carcinoma cells, but not in normal human or rat kidneys. Chromosome assignment was to RNO 13 in the rat, and HSA 1. This "Niban" gene is a candidate as a marker for renal tumor, especially early-stage renal carcinogenesis.

Indexed as

Genes, Tumor SuppressorPolymorphism, GeneticAmino Acid SequenceAnimalsBase SequenceCloning, MolecularDNA, ComplementaryHumansKidney NeoplasmsMesothelinMolecular Sequence DataMutationRatsRepressor ProteinsTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsDNA, ComplementaryMesothelinMsln protein, ratRepressor ProteinsTSC2 protein, humanTsc2 protein, ratTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Identifiers

PMID11011112
PMCPMC5926447
OpenAlexW2054814184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.